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PHeart Rhythm Disorders
igh Sensitivity C-Reactive Protein
Novel Predictor for Recurrence of
trial Fibrillation After Successful Cardioversion
oseph F. Malouf, MD, Ravi Kanagala, MD, Faisal O. Al Atawi, MD, A. Gabriela Rosales, MS,
iane E. Davison MA, RN, Narayana S. Murali, MBBS, Teresa S. M. Tsang, MD,
rishnaswamy Chandrasekaran, MD, Naser M. Ammash, MD, Paul A. Friedman, MD,
irend K. Somers, MD, PHD
ochester, Minnesota
OBJECTIVES We sought to test the hypothesis that C-reactive protein (CRP) can predict the recurrence of
atrial fibrillation (AF) after successful electrical cardioversion (CV).
BACKGROUND In patients with AF, CRP levels are predictive of immediate failure of CV.
METHODS We prospectively measured high-sensitivity CRP in 67 patients with AF or atrial flutter who
underwent successful electrical CV.
RESULTS At one-month follow-up, 22 patients (33%) had recurrence of their arrhythmia. Arrhythmia
recurrence was associated with significantly higher pre-CV CRP levels (odds ratio [OR] 1.84;
95% confidence interval [CI] 1.14 to 2.98; p  0.013) even after adjusting for age (OR 2.22;
95% CI 1.25 to 3.93; p  0.006), for gender (OR 1.89; 95% CI 1.16 to 3.09; p  0.011), or
duration of arrhythmia (OR 1.86; 95% CI 1.13 to 3.07; p 0.015). On multivariate analysis,
CRP was the only independent predictor of arrhythmia recurrence (OR 2.19; 95% CI 1.05
to 4.55; p  0.036).
CONCLUSIONS Our data suggest that high levels of CRP are associated with an increased risk of recurrence
of AF within one month. These data support the hypothesis that anti-inflammatory
interventions may help in maintenance of normal sinus rhythm after CV. These data also may
have implications for the identification of patients who are most likely to experience
substantial benefit from CV therapy for AF. (J Am Coll Cardiol 2005;46:1284–7) © 2005
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.053by the American College of Cardiology Foundation
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Cardioversion (CV) frequently is used to restore sinus
hythm in patients with persistent atrial fibrillation (AF),
articularly if new in onset. However, despite the very high
nitial success rate associated with CV, early relapse is
ommon, with as many as two-thirds of AF recurrences
ccurring within the first month (1–3). Similar observations
ave been made with atrial flutter (1).
Recent studies have implicated systemic inflammation in
he genesis and maintenance of atrial arrhythmias (4–9).
-reactive protein (CRP) is a sensitive but nonspecific
arker of systemic inflammation (4–9). C-reactive protein
evels predict the likelihood of new-onset AF (4), are
levated in patients with AF compared with patients in
inus rhythm (4,6,7), and are predictive of immediate failure
f both electrical (9) and chemical (7) CV in restoration of
ormal sinus rhythm. We tested the hypothesis that CRP is
redictive of recurrence of AF after successful electrical CV.
ETHODS
e prospectively measured high-sensitivity CRP in pa-
ients with AF or atrial flutter who underwent successful
From the Division of Cardiovascular Diseases, Mayo Clinic College of Medicine,
ochester, Minnesota.m
Manuscript received March 24, 2005; revised manuscript received May 28, 2005,
ccepted June 6, 2005.lectrical CV. Success was defined as sinus rhythm docu-
ented in the clinical record and/or by the electrocardio-
ram upon discharge from hospital. Patients with history of
ny previous CV, recent infection, surgery within 60 days,
r acute coronary syndrome within a month before collec-
ion of the blood sample were excluded. After obtaining
ritten consent, the CRP sample was drawn before sedation
or CV. Sixty-seven patients who met all the inclusion
riteria were enrolled in the study. All patients were pro-
pectively followed for recurrence of AF or atrial flutter up
o one month after CV. Arrhythmia recurrence was con-
rmed either by a physician examination and electrocardio-
raphic monitoring or a phone interview with confirmatory
eview of documents and a fax of the electrocardiogram sent
y primary care providers. This study was approved by the
ayo Clinic Institutional Review Board for Human Subject
esearch.
RP assay. C-reactive protein was measured on the Hita-
hi 912 (Roche Diagnostics, Indianapolis, Indiana) assay
ystem using the Kamiya K-assay (Kamiya Biomedical
orp., Seattle, Washington), which quantitatively deter-
ines CRP by a latex particle-enhanced immunoturbidi-
etric assay. Serial dilutions of patient serum samples at the
ayo Clinic laboratory have demonstrated that the Kamiya
RP method is linear to 0.015 mg/dl (10). Values 0.015
g/dl are reported as 0.015 in our study.
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October 4, 2005:1284–7 CRP and Cardioversion Successtatistical analysis. Continuous variables are reported as
eans  standard deviation whereas categorical variables
re reported as numbers and percentages. Univariate and
ultivariate associations of the variables reported in Table 1
ith the end point were assessed using logistic regression.
he multivariate model was created in three steps. We first
ssessed which factors were independently associated with
he CRP levels by using stepwise linear regression with
ntry and retention in the model set at a significance level of
.15 and 0.05, respectively. Second, we selected variables
hat were associated independently with the end point,
ecurrence of AF, by using stepwise logistic regression with
he same specifications mentioned previously. Finally, we
Abbreviations and Acronyms
AF  atrial fibrillation
BB  beta blockers
CCB  calcium channel blockers
CI  confidence interval
CRP  C-reactive protein
CV  cardioversion
OR  odds ratio
able 1. Patient Characteristics
Variable
No Recurrence
One Month (n
ale gender 30 (67%)
ge, yrs 72  8
MI, kg/m2 (n  66) 28  5
trial fibrillation 33 (73%)
trial flutter 12 (27%)
istory of atrial fibrillation (n  61) 20 (48%)
istory of atrial flutter (n  60) 7 (17%)
RP (mg/l) 6.0  15.
alvular disease 26 (58%)
VA/TIA 3 (7%)
ilated cardiomyopathy (n  52) 6 (16%)
umulative Joules (n  65) 151  12
aximum Joules (n  65) 73  36
istory of heart failure 8 (18%)
istory of diabetes mellitus (n  62) 9 (21%)
istory of hypertension 28 (62%)
istory of coronary artery disease 14 (31%)
VEF (n  50) 46  15
re-CV heart rate (n  57)* 81  18
ost-CV heart rate (n  62) 60  9
re-CV class IC 1 (2%)
re-CV CCB 8 (18%)
re-nondihydropyridine 6 (13%)
re-propafenone 1 (2%)
ismissal CCB (n  61) 8 (19%)
ismissal beta-blockers (n  61) 30 (71%)
ismissal diuretic (n  59) 19 (46%)
ismissal nondihydropyridine (n  61) 5 (12%)
ype of recurrent arrhythmia
Atrial fibrillation recurrence
Atrial flutter recurrence
UndeterminedMI  body mass index; CCB  calcium channel blocker; hs-CRP  high-sensitivity C-r
entricular ejection fraction; TIA  transient ischemic attack.stimated the association of CRP levels with the end point
fter adjusting for the variables selected in the first and
econd steps. Odds ratios (ORs) and their associated 95%
onfidence intervals (CIs) were estimated. We considered p
0.05 as statistically significant.
ESULTS
re-CV baseline data are listed in Table 1. Estimated
uration of the arrhythmia was less than one month in 35
atients (52%), more than one month in 32 patients (48%),
nd more than one year in 2 patients (3%). Twenty-two
atients (33%) had recurrence of AF or atrial flutter at one
onth follow-up. Arrhythmia recurrence was associated
ith significantly higher pre-CV CRP levels (OR 1.84; 95%
I 1.14 to 2.98; p 0.013) even after adjusting for age (OR
.22; 95% CI 1.25 to 3.93; p  0.006), for gender (OR
.89; 95% CI 1.16 to 3.09; p  0.011), or for duration of
rrhythmia (OR 1.86; 95% CI 1.13 to 3.07; p  0.015).
ther univariate predictors of arrhythmia recurrence in-
luded higher pre-CV mean heart rate and pre-CV use of
lass IC antiarrhythmic drugs or calcium channel blockers
CCBs) (Table 2). An increase in arrhythmia recurrence was
in
)
Recurrence Within
One Month (n  22)
Total
(n  67)
14 (64%) 44 (66%)
72  10 72  9
30  7 29  6
17 (77%) 50 (75%)
5 (23%) 17 (25%)
12 (63%) 32 (53%)
5 (26%) 12 (20%)
10.7  13.7 7.5  15.2
10 (46%) 36 (54%)
3 (14%) 6 (9%)
4 (29%) 10 (19%)
140  161 147  139
70  40 72  37
5 (23%) 13 (19%)
4 (21%) 13 (21%)
12 (55%) 40 (60%)
7 (32%) 21 (31%)
45  16 45  15
91  19 84  19
63  11 61  10
4 (18%) 5 (8%)
9 (41%) 17 (25%)
8 (36%) 14 (21%)
4 (18%) 5 (8%)
8 (42%) 16 (26%)
9 (47%) 39 (64%)
5 (28%) 24 (41%)
7 (37%) 12 (20%)
17 (77%)
3 (14%)
2 (9%)With
 45
8
9eactive protein; CV  cardioversion; CVA  cerebrovascular accident; LVEF  left
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CRP and Cardioversion Success October 4, 2005:1284–7oted among patients discharged on nondihydropyridine
CB (OR 4.32; 95% CI 1.15 to 16.15; p  0.030) and a
rend toward less arrhythmia recurrence among patients
ischarged on beta-blockers (BBs) (OR 0.36; 95% CI 0.12
o 1.11; p  0.07). On multivariate analysis (Table 3), CRP
as the only independent predictor of arrhythmia recur-
ence (OR 2.19; 95% CI 1.05 to 4.55; p  0.036).
ISCUSSION
n this study of patients with AF or atrial flutter who
nderwent successful electrical CV, pre-CV CRP was an
ndependent predictor of arrhythmia recurrence one month
fter CV. Dernellis and Panaretou (7) showed that CRP
evels are higher in patients who failed pharmacologic CV
ompared with patients who underwent successful CV.
onway et al. (9) found that CRP levels before CV are a
redictor of initial direct current CV success but not
redictive of maintenance of sinus rhythm at two months’
ollow-up.
Although several recent studies support a cause-effect
ssociation between inflammation and atrial arrhythmias
4–9), our data are the first to implicate increased CRP in
ailure of maintenance of sinus rhythm after CV. In patients
ndergoing cardiopulmonary bypass, postoperative CRP
evels, levels of CRP-complement complexes, and incidence
f postoperative atrial arrhythmias peaked at the same time
5). In the nonoperative setting, CRP levels were higher in
atients with AF compared with control patients in sinus
hythm (4,6,7), higher in patients with persistent AF
ompared with patients with paroxysmal AF (6,7), and
igher in patients with symptomatic AF compared with
symptomatic AF (7). Elevated CRP in patients in sinus
hythm predicted increased risk for developing future AF (4).
The hypothesis that ongoing inflammation can lead to
tructural remodeling of the atria, thus promoting persis-
ence or recurrence of AF (6,7), is supported by histologic
vidence of myocarditis in patients with lone AF (11).
herefore, anti-inflammatory therapy may conceivably
odulate AF recurrence or persistence. Indeed, in patients
able 2. Univariate Associations for Recurrence at One Month
Variable
Odds
Ratio 95% CI
p
Value
RP-log 1.84 1.14–2.98 0.013
re-CV nondihydropyridine 3.71 1.09–12.61 0.035
re-CV propafenone 9.77 1.02–93.53 0.048
ismissal nondihydropyridine 4.32 1.15–16.15 0.030
ot significant: gender; age; body mass index; New York Heart Association
unctional class; history of hypertension; diabetes; cerebrovascular accident/transient
schemic attack or dilated cardiomyopathy; log(max Joules); left ventricular ejection
raction; valvular disease; pre-CV angiotensin receptor blockers; angiotensin-
onverting enzyme inhibitors; amiodarone; beta-blockers; dihydropyridine calcium
hannel blockers; diuretics; heart rate; lanoxin, sotalol, or statins; and dismissal
iuretics or beta-blockers.
CI  confidence interval; CV  cardioversion; hs-CRP  high-sensitivity
-reactive protein.ith symptomatic persistent AF who undergo successful eV, treatment with low-dose corticosteroids reportedly
educed the incidence of AF recurrence compared with
ntreated control subjects who had similar CRP levels
efore CV. Although steroid therapy was associated with a
ignificant decrease in CRP levels and post-CV CRP levels
orrelated with risk of AF recurrence, it is not known
hether the attenuated recurrence could be explained by
ther effects of steroid therapy.
Our data also highlight a possible role for the autonomic
ervous system in post-CV recurrence of AF (12). We
ound that patients at risk for recurrence had a faster heart
ate before CV. Adrenergic stimulation may contribute to
alcium overload and AF recurrence (12). There are several
eports of a protective BB effect against AF relapses after
V. However, reports on the effects of CCBs after CV are
onflicting (3,7,13–15). Although both nondihydropyridine
CBs and BBs slow heart rate, the increased arrhythmia
ecurrence with nondihydropyridine CCBs and a trend
oward less recurrence with BBs highlights the potential
ole of the autonomic nervous system in arrhythmia recur-
ence and the possible benefit of direct adrenergic blockade,
hich also raises the possibility of an association between
eightened adrenergic tone and inflammation as measured
y CRP. We could not establish a salutary effect of statin
herapy on post-CV early arrhythmia recurrence, which is
onsistent with a previous report (16).
tudy limitations. Our data will need to be confirmed in
arger studies with extended follow-up durations. We also
annot exclude effects of differences in left atrial dimensions
r sleep apnea on the relationships we report. Nonetheless,
he integrity of our study design and validity of our findings
re supported by our confirmation of interactions between
ondihydropyridine CCB and BB therapy with likelihood
f AF recurrence after CV, as noted in earlier studies.
onclusions. Our data demonstrate that high levels of
RP are associated with an increased risk of recurrence of
F within one month of CV, supporting the overall concept
f systemic inflammation as an important etiologic mecha-
ism in the pathogenesis of AF and the possibility that
nti-inflammatory interventions may help in maintenance
f normal sinus rhythm after CV. These data also may have
mplications for identification of patients most likely to
able 3. Multivariate Logistic Model for Recurrence at One
onth
Variable
Odds
Ratio 95% CI
p
Value
ge 0.95 0.88–1.02 0.17
ale gender 1.16 0.29–4.58 0.83
ismissal nondihydropyridine 2.95 0.68–12.75 0.15
ismissal diuretic 0.30 0.07–1.29 0.11
RP-log 2.19 1.05–4.55 0.036
ultivariate analysis—model: age and gender were forced into the model. Bold
ndicates significant p value.
CI  confidence interval; CRP  C-reactive protein.xperience sustained benefit from CV therapy for AF.
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